SCHEDULE: Federated Hermes Discloses Stake in aTyr Pharma

Federated Hermes, Inc. and associated entities have filed an amended Schedule 13G, reporting beneficial ownership of 8,509,678 shares, representing 8.68% of aTyr Pharma Inc.'s common stock.

Summary

• This filing is an amendment to a Schedule 13G, indicating a change in beneficial ownership reporting for aTyr Pharma Inc. common stock.
• Federated Hermes, Inc., along with the Voting Shares Irrevocable Trust, Thomas R. Donahue, Ann C. Donahue, and J. Christopher Donahue, are reporting their beneficial ownership.
• The total number of shares beneficially owned by these reporting persons is 8,509,678.
• This ownership represents 8.68% of the class of securities.
• Federated Hermes, Inc. is identified as a parent holding company or control person.
• The Voting Shares Irrevocable Trust, along with Thomas R. Donahue, Ann C. Donahue, and J. Christopher Donahue (as trustees), collectively exercise voting control over Federated Hermes, Inc.
• The reporting persons explicitly disclaim beneficial ownership of the securities held by managed funds, stating that the report should not be construed as an admission of beneficial ownership.
• The filing date for this amendment is June 30, 2026, with signatures dated July 8, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral; it's a standard disclosure of significant institutional ownership without specific operational or financial performance data from the company itself.

Positives

• Significant stake reported by a major financial institution, Federated Hermes, Inc., indicating confidence or strategic interest in aTyr Pharma.
• The reporting persons collectively hold a substantial 8.68% stake, which could imply a degree of influence or a notable investment position.

Negatives

• The filing is an amendment, which could imply a change in holdings or reporting strategy, though the specific nature of the change is not detailed beyond the updated ownership percentage.
• The explicit disclaimer of beneficial ownership for securities held by managed funds suggests a complex ownership structure and potential separation of control from direct beneficial interest for certain assets.

Risks

• The disclaimer of beneficial ownership for managed funds could indicate potential future divestments or changes in investment strategy by those funds, which might impact aTyr Pharma's stock.
• The concentration of voting power within the Voting Shares Irrevocable Trust and its trustees, while disclosed, represents a key point of control that could influence corporate actions.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from aTyr Pharma Inc. It is a disclosure of beneficial ownership by Federated Hermes and associated entities.

Management Comments

• In accordance with Rule 13d-4 under the Exchange Act, Federated Hermes, Inc.; the Voting Shares Irrevocable Trust; Thomas R. Donahue; Ann C. Donahue; and J. Christopher Donahue declare that this report should not be construed as an admission that any of them is the beneficial owner of the securities held by any of the Managed Funds, and each of Federated Hermes, Inc.; the Voting Shares Irrevocable Trust; Thomas R. Donahue; Ann C. Donahue; and J. Christopher Donahue expressly disclaim beneficial ownership of such securities.
• The reporting persons declare that the joint filing of Schedule 13G shall not be construed as an admission that the reporting persons named herein constitute a group for purposes of Regulation 13D-G of the Securities Exchange Act of 1934, nor is a joint venture for purposes of the Investment Company Act of 1940.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and investment funds accumulating significant stakes in public companies. Federated Hermes' filing indicates a substantial investment in aTyr Pharma, placing it among the significant shareholders. The nature of the filing (amendment) suggests ongoing portfolio management by Federated Hermes.

Stakeholder Impact

• Shareholders: The filing confirms a significant institutional investor's stake, which can be viewed positively as a sign of confidence, but also raises questions about the investor's intentions (e.g., passive investment vs. active engagement).
• Management: The presence of a large shareholder like Federated Hermes may influence management's strategic decisions and corporate governance practices.
• Creditors: No direct impact is indicated by this filing.

Next Steps

• Continued monitoring of Federated Hermes' stake in aTyr Pharma for any further changes or disclosures.
• Analysis of aTyr Pharma's own SEC filings for operational updates and financial performance that may have influenced Federated Hermes' investment.

Key Dates

Keywords

aTyr Pharma, Schedule 13G, Federated Hermes, beneficial ownership, common stock, investment, holding company, voting control, SEC filing